

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Aliskiren for hypertension

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals Ltd (aliskiren) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Age Concern England • Black and Ethnic Minority Diabetes Association (BEMDA) • Black Health Agency (BHA) • Blood Pressure Association • British Cardiac Patients Association • British Hypertension Society • Cardiac Risk in the Young • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Diabetes UK • Equalities National Council • HEART UK • Muslim Council of Great Britain • Muslim Health Network • Network of Sikh Organisations UK • Overweight and Obesity Organisation • Specialised Healthcare Alliance • South Asian Health Foundation • The Stroke Association • TOAST (The Obesity Awareness and Solutions Trust) 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • A. Menarini Pharma UK S.R.L. (Nebivolol) • Abbott Laboratories Ltd (Captopril and hydrochlorothiazide, Trandolapril, Verapamil, Verapamil and trandolapril) • Actavis UK Ltd (Felodipine) • Alliance Pharmaceuticals (Chlorthalidone) • Amdipharm (Pindolol, Pindolol and clopamide, Oxprenolol) • Astellas Pharma Ltd (Nicardipine) • AstraZeneca UK Ltd (Metoprolol, Propranolol, Atenolol, Lisinopril, Felodipine)

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of aliskiren for the treatment of hypertension

Issue date: September 2007

Page 1 of 9

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Weight Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiac Care • British Association for Services to the Elderly • British Cardiovascular Interventional Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • Community Practitioners' and Health Visitors Association • Coronary Prevention Group • National Heart Forum (UK) • Nurses Hypertension Association • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Physicians' Cardiology Committee • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • Society for Cardiological Science and Technology [BCS affiliated] • Society of Cardiothoracic Surgeons of Great Britain and Ireland • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Rhondda Cynon Taff LHB • Stockport PCT • Welsh Assembly Government 	<ul style="list-style-type: none"> • Bayer plc (Nifedipine, Nifedipine and Atenolol) • Boehringer Ingelheim Ltd (Telmisartan, Lacidipine, Clonidine) • Bristol-Myers Squibb (Captopril, Captopril and hydrochlorothiazide, amiloride hydrochloride and hydrochlorothiazide, Fosinopril, Irbesartan, Irbesartan and hydrochlorothiazide, Lisinopril) • Cephalon Ltd (Verapamil, Dilzem) • Daiichi Sankyo UK Ltd (Olmesartan medoxomil) • Discovery Pharmaceuticals Ltd (Ramipril, Amlodipine, Doxazosin) • Forest Laboratories UK Ltd (Nisoldipine) • Genus Pharmaceuticals (Diltiazem, Nifedipine, Felotens) • Meda Pharmaceuticals (Xipamide) • Merck, Sharp and Dohme Ltd (Timolol maleate, amiloride hydrochloride and hydrochlorothiazide, Enalapril, Losartan, Aromatic-amino-acid decarboxylase inhibitor, Adrenergic antihypertensive medication) • MerckSerono (Bisoprolol, Diltiazem) • Napp Pharmaceuticals Ltd (Diltiazem) • Novartis Pharmaceuticals UK Ltd (Valsartan, Valsartan and hydrochlorothiazide, Metoprolol) • Pfizer Ltd (Hydrochlorothiazide and Quinapril, Quinapril, Amlodipine, Doxazosin, Prazosin) • Pharmacia Ltd (Metoprolol tartrate and hydrochlorothiazide, Peripheral vasodilator) • Recordati Pharmaceuticals Ltd (Lercanidipine) • Roche Products Ltd (Carvedilol, Cilazapril, Loop diuretic) • Rosemont Pharmaceuticals Ltd (Propranolol, Verapamil, Loop diuretic)

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of aliskiren for the treatment of hypertension

Appendix C

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Sanofi-Aventis (Metolazone, Nadolol, Acebutolol, Ramipril, Ramipril and felodipine, Irbesartan, Irbesartan and hydrochlorothiazide, Diltiazem, Loop diuretic and potassium-sparing diuretic) • Schwarz Pharma Ltd (Moexipril) • Servier Laboratories Ltd (Indapamide, Perindopril) • Shire Pharmaceuticals Ltd (Indoramin) • Solvay Healthcare Ltd (Eprosartan, Imidazoline agonist) • Sovereign Medical (Bendroflumethiazide, Peripheral vasodilator) • Takeda UK Ltd (Candesartan cilexetil) • UCB Pharma Ltd (Labetalol, Coracten) • Valeant Pharmaceuticals Ltd (Timolol) • Winthrop Pharmaceuticals UK Ltd (Celiprolol) • Wockhardt UK Ltd (Atenolol) • Wyeth Pharmaceuticals (Bisoprolol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research [BCS affiliated] • Cardiovascular Diseases Specialist Library (CVDSL) • Cochrane Hypertension Group • European Council for Cardiovascular Research • Policy Research Institute on Ageing and Ethnicity <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • (none)

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of aliskiren for the treatment of hypertension

Issue date: September 2007

Page 3 of 9

Appendix C

Consultees	Commentators (no right to submit or appeal)
	<u>Associated Public Health Groups</u> <ul style="list-style-type: none">• (none)

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of aliskiren for the treatment of hypertension

Issue date: September 2007

Page 4 of 9

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the topic.

Consultees	
Manufacturer	Generic Name
Novartis Pharmaceuticals Ltd	aliskiren
Commentators	
Manufacturer	Generic Name
A. Menarini Pharma UK S.R.L.	Nebivolol
Abbott Laboratories Ltd	Captopril and hydrochlorothiazide, Trandolapril, Verapamil, Verapamil and trandolapril
Actavis UK Ltd	Felodipine

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of aliskiren for the treatment of hypertension

Issue date: September 2007

Page 6 of 9

Appendix C

Alliance Pharmaceuticals	Chlorthalidone
Amdipharm	Pindolol, Pindolol and clopamide, Oxprenolol
Astellas Pharma Ltd	Nicardipine
AstraZeneca UK Ltd	Metoprolol, Propranolol, Atenolol, Lisinopril, Felodipine
Bayer plc	Nifedipine, Nifedipine and Atenolol
Boehringer Ingelheim Ltd	Telmisartan, Lacidipine, Clonidine
Bristol-Myers Squibb	Captopril, Captopril and hydrochlorothiazide, amiloride hydrochloride and hydrochlorothiazide, Fosinopril, Irbesartan, Irbesartan and hydrochlorothiazide, Lisinopril
Cephalon Ltd	Verapamil, Dilzem
Daiichi Sankyo UK Ltd	Olmesartan medoxomil
Discovery Pharmaceuticals Ltd	Ramipril, Amlodipine, Doxazosin
Forest Laboratories UK Ltd	Nisoldipine
Genus Pharmaceuticals	Diltiazem, Nifedipine, Felotens
Meda Pharmaceuticals	Xipamide
Merck, Sharp and Dohme Ltd	Timolol maleate, amiloride hydrochloride and hydrochlorothiazide, Enalapril, Losartan, Aromatic-amino-

Appendix C

	acid decarboxylase inhibitor, Adrenergic antihypertensive medication
MerckSerono	Bisoprolol, Diltiazem
Napp Pharmaceuticals Ltd	Diltiazem
Novartis Pharmaceuticals UK Ltd	Valsartan, Valsartan and hydrochlorothiazide, Metoprolol
Pfizer Ltd	Hydrochlorothiazide and Quinapril, Quinapril, Amlodipine, Doxazosin, Prazosin
Pharmacia Ltd	Metoprolol tartrate and hydrochlorothiazide, Peripheral vasodilator
Recordati Pharmaceuticals Ltd	Lercanidipine
Roche Products Ltd	Carvedilol, Cilazapril, Loop diuretic
Rosemont Pharmaceuticals Ltd	Propranolol, Verapamil, Loop diuretic
Sanofi-Aventis	Metolazone, Nadolol, Acebutolol, Ramipril, Ramipril and felodipine, Irbesartan, Irbesartan and hydrochlorothiazide, Diltiazem, Loop diuretic and potassium-sparing diuretic
Schwarz Pharma Ltd	Moexipril
Servier Laboratories Ltd	Indapamide, Perindopril

Appendix C

Shire Pharmaceuticals Ltd	Indoramin
Solvay Healthcare Ltd	Eprosartan, Imidazoline agonist
Sovereign Medical	Bendroflumethiazide, Peripheral vasodilator
Takeda UK Ltd	Candesartan cilexetil
UCB Pharma Ltd	Labetalol, Coracten
Valeant Pharmaceuticals Ltd	Timolol
Winthrop Pharmaceuticals UK Ltd	Celiprolol
Wockhardt UK Ltd	Atenolol
Wyeth Pharmaceuticals	Bisoprolol